On March 19, 2019 Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, reported an upcoming oral presentation at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from March 29 – April 3, 2019 at the Georgia World Conference Center in Atlanta, Georgia (Press release, Nurix Therapeutics, MAR 19, 2019, View Source [SID1234534497]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ORAL PRESENTATION DETAILS
Presentation Title: Genetic and pharmacologic evaluation of the ubiquitin ligase CBL-B as a small-molecule, tumor immunotherapy target
Session Category: Experimental and Molecular Therapeutics
Session Title: Preclinical Drug Development
Date: Monday, April 1, 2019
Time: 3:50 p.m.-4:05 p.m. EDT
Location: Georgia World Conference Center, Room B206